Benitec Biopharma Inc. (BNTC): Capital Expenditures
$105.0K
Year ended 2026-06-30
n/m
3-year compound annual growth
-13.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $105.0K | +483.3% | 2026-09-14, From 2025-07-01 |
| 2025-06-30 | $18.0K | -89.9% | 2026-09-14, From 2024-07-01 |
| 2024-06-30 | $179.0K | n/m | 2026-03-20, From 2023-07-01 |
| 2023-06-30 | $1.0K | -92.3% | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | $13.0K | -94.1% | 2023-09-21, From 2021-07-01 |
| 2021-06-30 | $221.0K | +132.6% | 2022-09-02, From 2020-07-01 |
| 2020-06-30 | $95.0K | -76.5% | 2021-09-20, From 2019-07-01 |
| 2019-06-30 | $404.0K | n/a | 2020-09-23, From 2018-07-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $105.0K | +483.3% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $24.0K | -98.8% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| PepGen Inc. (PEPG) | 2025-12-31 | $264.0K | -46.9% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $1.74M | +55.5% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $12.0K | -65.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $50.0K | -94.5% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $7.0K | n/a |
Compare BNTC, ANRO, LXRX, PEPG side by side · Screen every company in Pharmaceutical Preparations ↗